Extended trial tests drug for lingering COVID heart condition
NCT ID NCT05918978
Summary
This study aimed to evaluate the long-term safety and effectiveness of efgartigimod in adults with post-COVID POTS, a condition causing dizziness and rapid heartbeat when standing. The trial enrolled 33 participants who had completed a previous 24-week study, giving them continued access to the medication. Researchers monitored side effects and tracked symptoms like fatigue, cognitive issues, and overall quality of life over time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POST-COVID POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Apex Trials Group
Fort Worth, Texas, 76104, United States
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
Johns Hopkins University
Baltimore, Maryland, 21205, United States
-
Metrodora Institute
West Valley City, Utah, 84119, United States
-
North Shore University HealthSystem
Glenview, Illinois, 60026, United States
-
Pioneer Clinical Research
Rosharon, Texas, 77583, United States
-
Standford Movement Disorder Center
Palo Alto, California, 94304, United States
-
UC Sand Diego Sulpizio Cardiovascular Center
La Jolla, California, 92037, United States
-
University Hospitals, Neurology Clinical Trials
Cleveland, Ohio, 44106, United States
Conditions
Explore the condition pages connected to this study.